Dr. Véronique Diéras presents SABCS 2025 results from the AMBRE trial evaluating abemaciclib plus endocrine therapy vs chemotherapy in HR+/HER2- metastatic breast cancer with high visceral tumor burden, showing a progression-free survival benefit with abemaciclib.
